Abiopharma

🔍 Grossman Adam S (Executive)

Company: ADMA BIOLOGICS, INC. (ADMA)

Report Date: 2026-02-09

Detailed Transactions and Holdings:

• Acquired 282,529 shares of Common Stock (Direct)
  Date: 2026-02-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,290,379.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-02-09 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,143,426.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-02-09 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 580,957.00 | Footnotes: F6
• Acquired 444,711 shares of Stock Option (right to buy) at $16.37 per share (Derivative)
  Date: 2026-02-09 | Code: A | Expires: 2036-02-09 | equity_swap_involved: 0 | shares_owned_after: 444,711.00 | transaction_form_type: 4 | Footnotes: F7

Footnotes:

• F1: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.
• F2: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
• F3: (continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
• F4: (continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
• F5: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
• F6: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
• F7: The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.